Close Menu

NEW YORK – Cancer early detection firm Delfi Diagnostics said on Wednesday that it has begun recruiting for a 1,700-person prospective multi-center case control trial of its lung cancer liquid biopsy screening test. The company has also received Breakthrough Device Designation for the test from the US Food and Drug Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.